Table 3 Results of the primary analysis for a simulated cohort of 1000 patients diagnosed with TB
No. of TB patients in cohort | No. with (pre-)XDR | No. (%) of (pre-) XDR diagnosed earlier c.t. base case | Total No. of IPM among cohort; % Change c.t. base case | No. of PNTPM; % Change c.t. base case | % of all IPM | Total cohort costsa (US$ 2013); % change c.t. base case | Diagnostic costs (US$ 2013); % of total costs | Deaths (n; % Change c.t. base case | Need for re-treatment (n)b | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base case | 1000 | 59 | 1,710 | 66 | 4 % | $3,557,923 | 0 % | $44,617 | 1.2 % | 39.1 | 125 | ||||
High-throughput MRD-assay: | |||||||||||||||
A. following culture | 1000 | 59 | 45 | 76 % | 1,603 | −6 % | 76 | +15 % | 5 % | $2,960,243 | −17 % | $39,837 | 1.3 % | 40.1 (+2.5 %) | 127 (+1.6 %) |
B. Improved analytical sensitivity | 1000 | 59 | 45 | 76 % | 1,617 | −5 % | 71 | +8 % | 4 % | $2,821,923 | −21 % | $48,816 | 1.7 % | 40.1 (+2.5 %) | 129 (+3.9 %) |
C. Improved clinical accuracy | 1000 | 59 | 57 | 96 % | 1,604 | −6 % | 50 | −24 % | 3 % | $2,937,299 | −17 % | $39,233 | 1.3 % | 40.1 (+2.5 %) | 124 (−0.4 %) |